We sought to determine the yield of whole exome sequencing (WES) in determining the genetic etiology of fetal pleural effusions. STUDY DESIGN: We examined a retrospective cohort series of all cases of fetal pleural effusions visualized by prenatal ultrasound at a single center between May 1, 2016 and May 31, 2017. Prenatal and postnatal medical records were examined for clinical presentation and diagnostic workup. Fetal pleural effusions attributed to twin sharing, red cell alloimmunization, or structural anomalies were excluded, as were cases with a genetic diagnosis confirmed by karyotype or microarray analysis. The remaining cases were offered WES. WES was performed on cases submitted for either clinical sequencing or sequencing under the Baylor-Hopkins Center for Mendelian Genomics' research sequencing platform. RESULTS: Twenty-four fetuses with pleural effusions were evaluated by prenatal ultrasound. Eleven cases (45.8%) were excluded due to twin-transfusion (3 cases), twin anemia polycythemia sequence (1 case), Rh disease (2 cases), congenital diaphragmatic hernia (2 cases), cystic pulmonary airway malformation (1 case), and fetal teratoma (2 cases). Six additional cases (25%) were excluded due to diagnoses of monosomy X (4 cases), trisomy 21 (1 case), and terminal 7q36 deletion/7p22 duplication (1 case). Of the remaining 7 cases, 5 underwent WES, including 3 parent-proband trios and 2 parent-proband-affected sibling quads. We identified a pathogenic variant in 1 case, a likely pathogenic variant in a second case, and 3 cases with variants of unknown significance with potential for reclassification based on expansion of phenotype (see table) . CONCLUSION: Following standard clinical evaluations, a causative etiology remained unknown in 29.2% of prenatally diagnosed pleural effusions. In the present series, WES identified a pathogenic variant in 20% of such cases. Additional variants identified by WES require validation studies for confirmation. WES should be considered in cases of fetal pleural effusions when the standard evaluation is not diagnostic. OBJECTIVE: Prenatal chromosomal microarray (CMA) is recommend by SMFM for fetuses with ultrasound anomalies. A limitation of CMA is findings of variants of uncertain significance (VUS). Our objective was to determine how many VUSs were associated with a well-known phenotype, and in each, the level of likelihood of an affected phenotype, with the ultimate goal to establish how many VUSs are truly uncertain. STUDY DESIGN: All patients who had prenatal CMA with a VUS reported at our center since 2014 were included. We categorized variants as: variable penetrance; a rare copy number variant (CNV) that includes a gene with a known phenotype; likely autosomal recessive (AR) carrier status; CNV size >1 Mb without disease-causing genes; mosaicism; and region (s) of homozygosity (ROH) >5 Mb or >3% of the genome. For each category, we considered whether the potential phenotype(s) associated with the VUS was known or uncertain. VUSs with variable penetrance, AR carrier status and mosaicism were considered to be associated with a well-described phenotype, while the others were not. We also determined the level of certainty regarding the likelihood of an affected phenotype, which determines our confidence in the information we could provide to the patient regarding the prognosis. VUSs with variable penetrance, AR carrier status, mosaicism and size >1Mb had a known likelihood of having a disease, so were considered to have high certainty in counseling. VUSs due to ROH are known to have a higher risk of Poster Session V ajog.org
Utility of chromosomal microarray in cases of non-immune hydrops fetalis
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